Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, GlaxoSmithKline Ink Data-Integration Deal

NEW YORK, Nov. 1 (GenomeWeb News) - GE Healthcare will help GlaxoSmithKline develop an informatics system to integrate data from internal and external drug-discovery R&D sources, the companies said today.

 

Under the deal, GlaxoSmithKline will be able to use GE Healthcare's GeneticXchange's DiscoveryHub data- and information-integration software in its genetics, discovery, and pre-clinical-development R&D groups.

 

Additionally, the deal calls for GE Healthcare and GlaxoSmithKline to design, develop, and support next-generation DiscoveryHub technology.

Financial terms of the deal were not disclosed.

 

For additional details about the deal, see this week's issue of BioInform, GenomeWeb News' sister publication.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more